Supernus Pharma Files Proxy Statement
Ticker: SUPN · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: SUPN
TL;DR
Supernus Pharma dropped its proxy statement for the June 16th shareholder meeting. Governance & exec pay details inside.
AI Summary
Supernus Pharmaceuticals, Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting on June 16, 2025. The filing outlines the company's governance and executive compensation details, as is standard for a DEF 14A filing. No specific financial figures or proposals are detailed in the provided header information.
Why It Matters
This filing provides shareholders with crucial information regarding company governance and executive compensation, enabling informed voting decisions at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy statement filing, not indicating any immediate financial or operational risks.
Key Players & Entities
- SUPERNUS PHARMACEUTICALS, INC. (company) — Registrant
- 0001104659-25-042531.txt (document) — Filing document name
- 20250430 (date) — Filing date
- 20250616 (date) — Annual meeting date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit shareholder votes on important matters such as the election of directors, executive compensation, and other corporate actions.
When is the annual meeting of Supernus Pharmaceuticals, Inc. scheduled?
The annual meeting of Supernus Pharmaceuticals, Inc. is scheduled for June 16, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 30, 2025.
What is the Central Index Key (CIK) for Supernus Pharmaceuticals, Inc.?
The Central Index Key (CIK) for Supernus Pharmaceuticals, Inc. is 0001356576.
Where is Supernus Pharmaceuticals, Inc. headquartered?
Supernus Pharmaceuticals, Inc. is headquartered at 9715 Key West Avenue, Rockville, MD 20850.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).